In a 36-week phase 2 trial, Eli Lilly’s investigational oral GLP-1 medicine orforglipron helped adults with obesity or overweight lose more weight on average than participants taking placebo. Digestive side effects were common, and larger, longer trials are needed to establish long-term safety, durability and how the pill compares with other treatments.
TLDR: Eli Lilly’s experimental once-daily pill orforglipron produced average weight loss of up to 14.7 percent over 36 weeks in a phase 2 trial, compared with 2.3 percent for placebo. Digestive side effects were common. The results are promising, but the drug needs larger, longer studies before its lasting benefits and risks are clear.
An experimental once-daily pill from Eli Lilly led to substantial weight loss in adults with obesity or overweight in a 36-week clinical trial, offering evidence that injectable medicines may not be the only way to deliver powerful appetite-regulating treatment. The drug, orforglipron, belongs to a class known as GLP-1 receptor agonists. Unlike peptide-based medicines such as semaglutide, it is a small molecule that can be taken orally without special fasting instructions. Most established drugs in this class are injections, so an effective tablet could offer another route of treatment.
The phase 2 study enrolled 272 adults in the United States and Japan who had obesity, or overweight with at least one weight-related health condition. Participants were randomly assigned to receive one of four daily doses of orforglipron or a placebo. They also received lifestyle counseling. The study was funded by Lilly, and results were published in The New England Journal of Medicine in 2023. Researchers followed participants for 36 weeks, assessing changes in body weight and monitoring safety. Random assignment reduces the likelihood that baseline differences explain outcomes attributed to treatment.
At the highest dose, participants taking orforglipron lost an average of 14.7 percent of their starting weight by week 36. The corresponding average loss in the placebo group was 2.3 percent. Weight loss increased with dose, a pattern that helps researchers understand how the medicine might be used and what trade-offs accompany stronger treatment. The group average does not describe every individual’s response; some participants lost more or less than that figure. The trial was relatively small and short, however, and its results do not establish how well the drug works over years or how it compares directly with approved injectable therapies.
Orforglipron works by activating the GLP-1 receptor, which is involved in regulating appetite, food intake and blood sugar. The medicine is designed to imitate a gut hormone signal that can increase feelings of fullness and influence digestion. These signals promote fullness and influence food intake, contributing to weight change alongside lifestyle counseling. Because the compound is a small molecule rather than a peptide, it may be easier to formulate as a tablet. That difference could simplify storage and use, although convenience alone does not show that a medicine is safer, more effective or more accessible in routine care.
Digestive problems were the most commonly reported side effects, including nausea, constipation and diarrhea. Such effects are also seen with other medicines in this class, and in the trial they were generally described as mild to moderate. More participants stopped treatment because of adverse effects in the orforglipron groups than in the placebo group. Digestive symptoms can affect whether patients continue treatment, making tolerability important alongside average weight loss. The study was not large enough to reliably detect uncommon harms, so larger and longer trials are needed to clarify the balance of benefit and risk.
The findings added to evidence that oral GLP-1 medicines could become another option for managing obesity, a chronic condition linked to diabetes, heart disease and other health problems. They do not mean that the pill is already an established treatment: at the time of these results, orforglipron remained investigational. Later-stage trials must test its effects in broader groups, examine durability and safety, and compare outcomes at different doses. Researchers will also need to determine whether a daily tablet can be delivered affordably and consistently. The practical value will depend on benefits, risks, cost and sustained access over time. The results mark a step toward expanding treatment choices, not a replacement for follow-up evidence or individualized medical care.
Susan Carter serves as a Senior Correspondent for Just Right News, where she leads the network’s comprehensive coverage of Health, Medicine, and Public Policy. With a career dedicated to dissecting the complexities of the American healthcare system, Susan brings a principled perspective to the most pressing debates of the day. Her reporting is characterized by a commitment to individual liberty, fiscal responsibility, and a healthy skepticism of government overreach, making her a vital voice for audiences seeking clarity in an increasingly regulated landscape.
Raised in Minneapolis, Minnesota, Susan’s professional outlook is deeply informed by the values of the American heartland. Growing up in the Twin Cities, she witnessed firsthand the importance of community-driven solutions and the resilience of the individual. This Midwestern foundation instilled in her a firm belief that the best answers to public policy challenges often come from local innovation and personal responsibility rather than top-down federal mandates. Her background allows her to translate complex legislative jargon into stories that resonate with families who value common sense and local autonomy.
Now based in Baltimore, Maryland, Susan operates from a unique vantage point at the intersection of medical innovation and urban policy. Living and working in a city renowned for its world-class medical institutions and significant public health challenges, she has a front-row seat to the realities of the modern healthcare landscape. Her proximity to these hubs of research and policy allows her to scrutinize how government intervention affects the quality of care and the freedom of medical professionals. In Baltimore, she sees the tangible results of policy decisions, using the city as a lens through which to examine the broader national health debate and the impact of federal spending on local communities.
As the lead for the acclaimed feature series “The Cost of Care,” Susan dives deep into the economic realities facing patients and providers alike. Her work focuses on the necessity of price transparency, the benefits of market competition, and the preservation of the sacred doctor-patient relationship. She is a staunch advocate for the idea that a well-informed public is the best defense against bureaucratic inefficiency. Through this series, she has exposed the hidden drivers of rising medical expenses, always seeking to empower the individual consumer over the massive institution.
Susan’s reporting on public policy is characterized by a commitment to rigorous inquiry and a focus on constitutional limits. Whether she is analyzing new pharmaceutical regulations, investigating the impact of federal health mandates, or exploring the future of medical technology, her goal remains the same: to provide Just Right News audiences with the facts they need to navigate a complex world. By blending her Midwestern sensibilities with the insights gained from her base in Maryland, Susan Carter has become a trusted authority for those who believe that personal freedom and public health are inextricably linked. Her work continues to challenge the status quo, advocating for a system that respects the taxpayer and prioritizes the patient.